AbbVie stock gains 1.11 percent as October earnings near

Published on 10/03/2026 at 22:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock was last at USD 262.82 on October 2, 2026, 2.44 percent below its 52-week high. Q2 revenue reached USD 16.99 billion, up 10.2 percent year over year.

Flatlay-Produktfoto mit generischen Blisterpackungen, Ampullen, Pipette und abstraktem Wertpapierschein — AbbVie Inc. US00287Y1091 Flatlay generische Blisterpackungen Ampullen Pipette Aktien Zertifikat und ISIN Karte, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) stock was last at USD 262.82 on the NYSE on October 2, 2026, up 1.11 percent from the prior close. The move leaves the share price 2.44 percent below its 52-week high of USD 269.39, while the next earnings date gives the market a defined checkpoint.

October earnings set the next test

According to Yahoo Finance on October 1, 2026, AbbVie will announce its third-quarter 2026 results before the market opens on October 30, 2026. The company will host its earnings call at 8:00 a.m. CT, giving investors a date to assess product momentum and updated expectations.

The October 2 price action adds a market signal to that calendar event. AbbVie ended the session reference period at USD 262.82, with an intraday range of USD 257.87 to USD 264.06 and volume of 5,541,012 shares.

Q2 revenue clears consensus

AbbVie generated USD 16.99 billion in second-quarter 2026 revenue, up 10.2 percent from the same quarter a year earlier, according to MarketBeat. Adjusted diluted EPS reached USD 3.65, exceeding the USD 3.61 consensus by USD 0.04.

The comparison matters because the revenue figure combines scale and acceleration: the quarterly total exceeded the USD 16.80 billion consensus estimate, while year-over-year growth remained double digit. AbbVie also set third-quarter 2026 EPS guidance at USD 3.840-3.880, according to MarketBeat.

Pipeline strength meets valuation risk

MarketBeat linked the recent share move to FDA approval of Juvmo for Parkinson's disease, positive long-term RINVOQ vitiligo data and continued pipeline activity. The same report identified Humira erosion, competition and the need for newer products to scale as counterweights to the growth narrative.

Analyst expectations remain higher than the reference price: MarketBeat cited a consensus rating of Moderate Buy and an average target of USD 272.66. That target is 3.75 percent above USD 262.82, so the October earnings release will test whether the product pipeline can support the premium valuation.

AbbVie stock stays near its yearly high

AbbVie stock was last at USD 262.82 on the NYSE on October 2, 2026, with a market capitalization of USD 464.3 billion. The 52-week range of USD 190.75 to USD 269.39 places the reference price near the upper end of its annual band.